RenovoRx CEO to Present at Global Investment Conference
LOS ALTOS, Calif., Aug. 27, 2024 — RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company recognized for its innovative precision oncology therapies via a local drug-delivery platform, has announced that CEO Shaun Bagai will be presenting at H.C. Wainwright’s 26th Annual Global Investment Conference. This prestigious event is set to take place in New York City from September 9-11, 2024, with Mr. Bagai's presentation scheduled for September 9, 2024, at 7:00 a.m. ET.
In his presentation, Mr. Bagai will showcase the company’s recent achievements, particularly the progress made in RenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial. This trial is crucial for assessing the effectiveness of the company’s proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, which targets the treatment of Locally Advanced Pancreatic Cancer (LAPC).
Presentation Details
Date: Monday, September 9, 2024
Time: 7:00 a.m. ET
Location: Lotte New York Palace Hotel, New York City
Speaker: Shaun Bagai, CEO
Importance of the TIGeR-PaC Clinical Trial
Mr. Bagai will also share insights into RenovoRx's ongoing search for new commercial opportunities related to its proprietary therapy platform technology, particularly the FDA-cleared RenovoCath delivery system, which has the potential to function as a stand-alone device. The RenovoCath device is designed for temporary vessel occlusion in various medical procedures, including arteriography and the infusion of chemotherapeutic drugs. In line with its commercial strategy, RenovoRx appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024.
Overview of RenovoRx's Clinical Innovations
RenovoRx is conducting the TIGeR-PaC clinical trial as a Phase III randomized multi-center study that specifically evaluates the TAMP™ platform for the treatment of LAPC. This trial utilizes RenovoRx’s first product candidate that employs TAMP technology, representing a groundbreaking investigational oncology drug-delivery system that incorporates the FDA-cleared RenovoCath device for administering the chemotherapy agent gemcitabine HCl directly to the tumor site.
Interim Analysis and Future Projections
The first interim analysis of the Phase III trial was completed in March 2023. Encouragingly, the Data Monitoring Committee has recommended that the study continue, highlighting the significance of TAMP technology for patients with LAPC. The study aims to achieve a primary endpoint that includes a six-month overall survival benefit while also focusing on minimizing side effects compared to standard treatments. The second interim analysis is expected to coincide with the estimated 52nd event, anticipated to occur in late 2024 or early 2025.
RenovoRx: Company Overview
RenovoRx is committed to developing advanced precision oncology solutions through a unique local drug delivery mechanism designed to address significant unmet medical needs. The TAMP™ therapy platform effectively delivers treatment directly to the tumor site, enhancing therapeutic outcomes while potentially reducing the toxicities typically associated with systemic IV therapy. The company boasts a robust pipeline, including a Phase III lead product candidate that is currently part of a U.S. investigational new drug application under the oversight of regulatory authorities.
Beyond its core clinical activities, RenovoRx is actively exploring commercialization opportunities utilizing its TAMP technology and the RenovoCath delivery system, independent of other oncology applications. RenovoRx remains dedicated to innovatively transforming cancer care and improving patient lives through pioneering therapeutic solutions.
Frequently Asked Questions
What will RenovoRx CEO Shaun Bagai present at the conference?
Mr. Bagai will discuss the company's recent accomplishments and provide insights into its TIGeR-PaC clinical trial, which focuses on treating locally advanced pancreatic cancer.
Where and when is the conference being held?
The H.C. Wainwright’s Global Investment Conference will take place from September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
What is the significance of the TIGeR-PaC trial?
The TIGeR-PaC trial assesses the effectiveness of the TAMP™ therapy platform in improving treatment outcomes for patients suffering from locally advanced pancreatic cancer.
Who was recently appointed to RenovoRx's Corporate Strategy team?
Ryan Witt was appointed as Senior Vice President of Corporate Strategy and Partnerships in June 2024.
What does the RenovoCath device do?
The RenovoCath device is utilized for temporary vessel occlusion in medical procedures such as arteriography, preoperative occlusion, and chemotherapy drug infusion.